Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...

The US Food and Drug Administration has approved Journavx, also known as suzetrigine 50 milligram oral tablets—a ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...

Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...

China’s healthcare regulator has pledged to investigate the quality of drugs under a new list covered by national ... evidence and clinical data on drug quality. “The prerequisite for listing ...

The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, the drugs at the center of the weight-loss craze.

Add articles to your saved list and come back to them any time ... has been charged with trafficking a drug of dependence – psilocin, the psychedelic agent in magic mushrooms.

Medicare says that the drug added up to more than $14 billion ... used drugs in Medicare by about 40% to 80% compared to their list price, though researchers estimate the actual savings were ...

The list of 15 drugs in the next round is below, in the order provided by HHS. According to the health department, about 5.3 million people with Medicare prescription drug coverage used at least ...